{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:10:58Z","timestamp":1778875858589,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:00:00Z","timestamp":1615593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010203","name":"Walter Reed Army Institute of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["NCT02646371"],"award-info":[{"award-number":["NCT02646371"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ebiom.2021.103308","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T03:02:14Z","timestamp":1617332534000},"page":"103308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine"],"prefix":"10.1016","volume":"66","author":[{"given":"Kristen A.","family":"Clarkson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawsar R.","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Alaimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Louis","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad K.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhra","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Brubaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Elwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahel","family":"Fr\u00f6lich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"DeNearing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailey P.","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Feijoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica Gambillara","family":"Fonck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4015-5694","authenticated-orcid":false,"given":"Robert W.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ebiom.2021.103308_bib0001","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to Shigella and enterotoxigenic escherichia coli diarrhoea: the global burden of disease study 1990-2016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103308_bib0002","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S1473-3099(18)30362-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the global burden of disease study 2016","volume":"18","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103308_bib0003","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1053\/j.gastro.2010.05.076","article-title":"Prolonged episodes of acute diarrhea reduce growth and increase risk of persistent diarrhea in children","volume":"139","author":"Moore","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0004","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2214-109X(18)30483-2","article-title":"Burden of enterotoxigenic escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis","volume":"7","author":"Anderson","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ebiom.2021.103308_bib0005","unstructured":"BCG. Vaccines to tackle drug resistant infections: An evaluation of R&D opportunities: Wellcome Trust & Boston Consulting Group, https:\/\/vaccinesforamr.org\/wp-content\/uploads\/2018\/09\/Vaccines_for_AMR.pdf. 2018."},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0006","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1017\/S0950268814000958","article-title":"Changing patterns and widening of antibiotic resistance in Shigella spp. over a decade (2000-2011), Andaman Islands, India","volume":"143","author":"Bhattacharya","year":"2015","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.ebiom.2021.103308_bib0007","unstructured":"World Health Organization (WHO) doivab. the 6th annual meeting of the WHO product development for vaccines advisory committee (PDVAC): executive summary of meeting and recommendations. https:\/\/www.who.int\/immunization\/research\/meetings_workshops\/pdvac_june19\/en\/, 2019."},{"key":"10.1016\/j.ebiom.2021.103308_bib0008","unstructured":"CDC. The threat of antibiotic resistance. https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf: Center for Disease Control and Prevention, 2019."},{"key":"10.1016\/j.ebiom.2021.103308_bib0009","unstructured":"(WHO) WHO. Global action plan on antimicrobial resistance. 2015. https:\/\/www.who.int\/antimicrobial-resistance\/global-action-plan\/en\/(accessed 2020 2020)."},{"issue":"8","key":"10.1016\/j.ebiom.2021.103308_bib0010","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.vaccine.2014.11.049","article-title":"An assessment of enterotoxigenic escherichia coli and Shigella vaccine candidates for infants and children","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.ebiom.2021.103308_bib0011","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","article-title":"Status of vaccine research and development for Shigella","volume":"34","author":"Mani","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103308_bib0012","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103308_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/infdis\/125.1.12","article-title":"Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection","volume":"125","author":"DuPont","year":"1972","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103308_bib0014","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103308_bib0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.inf.0000078156.03697.a5","article-title":"Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children","volume":"22","author":"Passwell","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0016","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect Immun"},{"issue":"36","key":"10.1016\/j.ebiom.2021.103308_bib0017","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase i study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103308_bib0018","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and Immunogenicity of a Candidate bioconjugate vaccine against Shigella flexneri 2a Administered to healthy adults: a single-blind, randomized phase i study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103308_bib0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/glycob\/cwz044","article-title":"Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate","volume":"29","author":"Ravenscroft","year":"2019","journal-title":"Glycobiology"},{"issue":"Supplement_8","key":"10.1016\/j.ebiom.2021.103308_bib0020","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1093\/cid\/ciz891","article-title":"Consensus report on Shigella controlled human infection model: clinical endpoints","volume":"69","author":"MacLennan","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103308_bib0021","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1128\/IAI.68.12.6624-6632.2000","article-title":"Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine","volume":"68","author":"Turbyfill","year":"2000","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103308_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00988-19","article-title":"Immune response characterization after controlled infection with lyophilized Shigella sonnei 53G","volume":"5","author":"Clarkson","year":"2020","journal-title":"mSphere"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00146-18","article-title":"Development, Interlaboratory evaluations, and application of a simple, high-throughput Shigella serum bactericidal assay","volume":"3","author":"Nahm","year":"2018","journal-title":"mSphere"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103308_bib0024","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/cyto.a.20864","article-title":"Low-cost, high-throughput, automated counting of bacterial colonies","volume":"77","author":"Clarke","year":"2010","journal-title":"Cytometry A"},{"key":"10.1016\/j.ebiom.2021.103308_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3762651","article-title":"Defining an optimal cut-point value in roc analysis: an alternative approach","volume":"2017","author":"Unal","year":"2017","journal-title":"Comput Math Methods Med"},{"issue":"23","key":"10.1016\/j.ebiom.2021.103308_bib0026","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/sim.4509","article-title":"Classification accuracy and cut point selection","volume":"31","author":"Liu","year":"2012","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103308_bib0027","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1086\/516452","article-title":"Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection","volume":"175","author":"Robin","year":"1997","journal-title":"J Infect Dis"},{"issue":"23\u201324","key":"10.1016\/j.ebiom.2021.103308_bib0028","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/S0264-410X(99)00136-X","article-title":"Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines","volume":"17","author":"Robin","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2021.103308_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60486-1","article-title":"Human antibody effector function","volume":"51","author":"Burton","year":"1992","journal-title":"Adv Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.coi.2012.03.014","article-title":"Vaccines against mucosal infections","volume":"24","author":"Holmgren","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103308_bib0031","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103308_bib0032","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4049\/jimmunol.158.2.574","article-title":"Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut","volume":"158","author":"Kantele","year":"1997","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103308_bib0033","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4049\/jimmunol.110.5.1307","article-title":"Local antibody response to poliovaccine in the human female genital tract","volume":"110","author":"Ogra","year":"1973","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103308_bib0034","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/171.1.198","article-title":"Parenteral influenza vaccination induces a rapid systemic and local immune response","volume":"171","author":"Brokstad","year":"1995","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103308_bib0035","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.vaccine.2011.11.035","article-title":"Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.ebiom.2021.103308_bib0036","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.162.8.5011","article-title":"Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus","volume":"162","author":"Herremans","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103308_bib0037","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/infdis\/171.4.1072-a","article-title":"IgA subclasses, and secretory component levels in oral fluid collected from subjects after parental influenza vaccination","volume":"171","author":"Brokstad","year":"1995","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103308_bib0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0264-410X(98)00193-5","article-title":"Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans","volume":"17","author":"Kantele","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2021.103308_bib0039","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fimmu.2013.00222","article-title":"Secretory IgA: designed for anti-microbial Defense","volume":"4","author":"Brandtzaeg","year":"2013","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103308_bib0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/CVI.00214-16","article-title":"Parenteral vaccination can be an effective means of inducing protective mucosal responses","volume":"23","author":"Clements","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"Supplement_8","key":"10.1016\/j.ebiom.2021.103308_bib0041","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1093\/cid\/ciz909","article-title":"Consensus report on Shigella controlled human infection model: immunological assays","volume":"69","author":"Kaminski","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103308_bib0042","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1128\/IAI.01021-09","article-title":"Assessment of the duration of protection in campylobacter jejuni experimental infection in humans","volume":"78","author":"Tribble","year":"2010","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103308_bib0043","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/CVI.00617-15","article-title":"Characterization of mucosal immune responses to enterotoxigenic escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407","volume":"23","author":"Chakraborty","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"36","key":"10.1016\/j.ebiom.2021.103308_bib0044","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2008.06.064","article-title":"A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. Coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC","volume":"26","author":"McKenzie","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103308_bib0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0950268812001677","article-title":"The Shigella human challenge model","volume":"141","author":"Porter","year":"2013","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103308_bib0046","first-page":"51","article-title":"Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering escherichia coli","volume":"26","author":"Ravenscroft","year":"2016","journal-title":"Glycobiology"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:32:57Z","timestamp":1778873577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":46,"alternative-id":["S2352396421001018"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103308","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103308"}}